Simulations Plus EBIT 2010-2025 | SLP
Simulations Plus ebit from 2010 to 2025. Ebit can be defined as earnings before interest and taxes.
Simulations Plus Annual EBIT
(Millions of US $) |
| 2024 |
$6 |
| 2023 |
$9 |
| 2022 |
$15 |
| 2021 |
$11 |
| 2020 |
$12 |
| 2019 |
$11 |
| 2018 |
$10 |
| 2017 |
$8 |
| 2016 |
$7 |
| 2015 |
$6 |
| 2014 |
$4 |
| 2013 |
$4 |
| 2012 |
$4 |
| 2011 |
$4 |
| 2010 |
$3 |
| 2009 |
$2 |
Simulations Plus Quarterly EBIT
(Millions of US $) |
| 2025-02-28 |
$3 |
| 2024-11-30 |
$0 |
| 2024-08-31 |
$-1 |
| 2024-05-31 |
$2 |
| 2024-02-29 |
$4 |
| 2023-11-30 |
$1 |
| 2023-08-31 |
$0 |
| 2023-05-31 |
$4 |
| 2023-02-28 |
$4 |
| 2022-11-30 |
$1 |
| 2022-08-31 |
$1 |
| 2022-05-31 |
$5 |
| 2022-02-28 |
$5 |
| 2021-11-30 |
$4 |
| 2021-08-31 |
$0 |
| 2021-05-31 |
$5 |
| 2021-02-28 |
$3 |
| 2020-11-30 |
$3 |
| 2020-08-31 |
$2 |
| 2020-05-31 |
$4 |
| 2020-02-29 |
$3 |
| 2019-11-30 |
$3 |
| 2019-08-31 |
$2 |
| 2019-05-31 |
$4 |
| 2019-02-28 |
$3 |
| 2018-11-30 |
$2 |
| 2018-08-31 |
$2 |
| 2018-05-31 |
$3 |
| 2018-02-28 |
$2 |
| 2017-11-30 |
$3 |
| 2017-08-31 |
$1 |
| 2017-05-31 |
$3 |
| 2017-02-28 |
$2 |
| 2016-11-30 |
$2 |
| 2016-08-31 |
$1 |
| 2016-05-31 |
$3 |
| 2016-02-29 |
$2 |
| 2015-11-30 |
$2 |
| 2015-08-31 |
$1 |
| 2015-05-31 |
$3 |
| 2015-02-28 |
$1 |
| 2014-11-30 |
$1 |
| 2014-08-31 |
$0 |
| 2014-05-31 |
$2 |
| 2014-02-28 |
$1 |
| 2013-11-30 |
$1 |
| 2013-08-31 |
$0 |
| 2013-05-31 |
$2 |
| 2013-02-28 |
$2 |
| 2012-11-30 |
$1 |
| 2012-08-31 |
$0 |
| 2012-05-31 |
$1 |
| 2012-02-29 |
$1 |
| 2011-11-30 |
$1 |
| 2011-08-31 |
$0 |
| 2011-05-31 |
$1 |
| 2011-02-28 |
$1 |
| 2010-11-30 |
$1 |
| 2010-08-31 |
$0 |
| 2010-05-31 |
$1 |
| 2010-02-28 |
$1 |
| 2009-11-30 |
$1 |
| 2009-08-31 |
$0 |
| 2009-05-31 |
$1 |
| 2009-02-28 |
$1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Computer and Technology |
Computer Software |
$0.554B |
$0.070B |
|
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. They have two other businesses, Words+, Inc. and FutureLab, which are based on its proprietary software technologies.
|
